FDA Approves Celexa For The Treatment of Depression
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




FDA Approves Celexa For The Treatment of Depression

NEW YORK, NY -- July 20, 1998 -- The United States Food and Drug Administration has approved Forest Laboratories’ and Parke-Davis’ Celexa(TM) (citalopram HBr) for the treatment of depression.

A highly-selective serotonin reuptake inhibitor (SSRI), Celexa is the best-selling antidepressant in 13 countries, including eight in Europe, where other SSRIs are also available.

Celexa has been proven effective and well tolerated in clinical trials involving more than 23,000 Celexa-treated patients, as well as by a decade of clinical use during which more than eight million people in 64 countries have been treated with Celexa.

The antidepressant effects of Celexa have been evaluated in several large, placebo-controlled trials, as well as a number of clinical studies comparing it with tricyclic antidepressants (TCAs) and other SSRIs. Results from these studies show that treatment with Celexa consistently and significantly improves symptoms of depression, regardless of patient age, race, or gender. In addition, two, six-month, double-blind, placebo-controlled studies have shown Celexa is significantly more effective than placebo in preventing relapse of depression.

Among Celexa-treated patients in clinical trials reporting side effects, those most frequently reported were nausea, dry mouth and sleepiness. As with all SSRIs, Celexa should not be taken together with monoamine oxidase inhibitors.

Clinical depression is a biologically-based illness that affects more than one in 10 Americans and is associated with greater levels of physical and social impairment than other chronic conditions such as asthma and heart disease. A study published in 1994 estimated that depression costs the nation more than $43 billion each year in absenteeism from work, lost productivity and direct treatment costs. Of particular importance is a growing body of evidence that untreated depression worsens the course of other medical illnesses, such as heart disease and pulmonary disease.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities